Back to top

cell-therapy: Archive

Sundeep Ganoria

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

REGNNegative Net Change BEAMPositive Net Change NTLANegative Net Change

Urmimala Biswas

Demographic Megatrend: Stocks Poised to Benefit From Global Aging

Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.

BSXNegative Net Change AMGNPositive Net Change EWNegative Net Change OHIPositive Net Change ABBVNegative Net Change CTREPositive Net Change ENSGNegative Net Change